clinical trial · NCT07571005
AMAZE 3: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Obstructive Sleep Apnoea Not Treated With Positive Airway Pressure Lose Weight and Improve Sleep Apnoea
Novo Nordisk A/S·phase3·recruiting·n = 300
ObesityOverweightObstructive Sleep ApnoeaNNC0487-0111Placebo (matched to NNC0487-0111)
brief summary
This study is being done to look at the efficacy and safety of NNC0487-0111 in participants with excess body weight and obstructive sleep apnoea not treated with positive airway pressure lose weight and improve sleep apnoea. There are 2 study treatments in this study taken as injections under the skin once a week. Participants will either get NNC0487-0111, (the treatment being tested) or Placebo (a treatment that has no active medicine in it) and which treatment participants get is decided by chance.
started
May 5, 2026
primary completion
Jul 12, 2028
completion
Oct 4, 2028
last updated
Jun 2, 2026
official title
Efficacy and Safety of NNC0487-0111 s.c. Once-weekly in Participants With Overweight or Obesity, and Obstructive Sleep Apnoea Not Treated With Positive Airway Pressure (AMAZE 3)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol